Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of Segment Information (Details)

v3.26.3
Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Total revenues $ 80,890     $ 69,462     $ 218,411 $ 224,480
Less:                
Cost of product sales 10,783     4,753     23,914 13,666
Provision for (benefit from) income taxes 4,224     (280)     13,522 154
Net income 13,185 $ 17,290 $ 8,654 27,900 $ 59,613 $ 11,446 39,129 98,959
Single reportable segment                
Segment Reporting [Line Items]                
Total revenues 80,890     69,462     218,411 224,480
Less:                
Employee related expenses 21,258     18,547     65,690 56,666
Commercial related expenses 9,444     6,303     23,568 18,915
Outside clinical trial related expenses 12,626     3,759     26,962 11,362
Cost of product sales 10,783     4,753     23,914 13,666
Consultants and third-party services 5,191     4,133     13,422 10,751
Other segment items 4,483     3,547     12,290 10,824
Interest (income) expense and other, net (304)     800     (86) 3,183
Provision for (benefit from) income taxes 4,224     (280)     13,522 154
Net income $ 13,185     $ 27,900     $ 39,129 $ 98,959